Agilent Technologies has joined the BioIT Alliance, a cross-industry group working together to improve biomedical information technology.
The alliance seeks to enable the pharmaceutical, biotechnology, equipment manufacturing and software industries to share best practices and develop standards for sharing biomedical data, improving collaboration and effectively managing life sciences knowledge. The early focus of the alliance has been on addressing data capture and data integration challenges that hinder the adoption of emerging life science technologies.
As a member of the alliance, Agilent will collaborate with other members on proof-of-concept applications that address critical bottlenecks in biomedical discovery. Included is the alliance's latest proof–of-concept, the Biomarkers Project, designed to simplify the process of identifying and validating genomic biomarkers, the characteristics that indicate the presence of a disease or the likely efficacy of a drug.
'Agilent's involvement in the BioIT Alliance will further strengthen our commitment to enable biotechnology and pharmaceutical companies to effectively integrate data and insights from multiple disciplines and measurement platforms,' said Nick Roelofs, vice president and general manager of life sciences, Agilent Technologies.
